查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984092

基因编辑技术市场：按技术平台、递送方式、疾病和应用分類的全球市场预测 – 2026-2032 年

Gene Editing Technologies Market by Technology Platform, Delivery Method, Disease Indication, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因编辑技术市值将达到 205.9 亿美元，到 2026 年将成长至 231.7 亿美元，到 2032 年将达到 540.8 亿美元，复合年增长率为 14.78%。

主要市场统计数据
基准年 2025 205.9亿美元
预计年份：2026年 231.7亿美元
预测年份 2032 540.8亿美元
复合年增长率 (%) 14.78%

对现代基因编辑进行简要概述，重点介绍技术进步、实用化的势头以及各领域相关人员的战略考虑因素。

过去十年，基因编辑技术已从一项前景看好的实验室技术发展成为变革生物医学研究、农业科学和工业生物技术的基础工具。核酸酶设计、递送系统和编辑精度的进步，使研究人员能够以前所未有的分辨率分析生物系统。同时，临床计画和转化研究正稳步从概念验证迈向治疗应用阶段。因此，各领域的相关人员正在重新评估其投资组合、投资重点和合作模式，以最大限度地发挥这些平台的科学和商业性潜力。

编辑化学、递送方法和监管合作的最新技术突破如何重塑创新路径和商业性伙伴关係。

基因编辑正经历一场变革性的转型，这得益于精准化学技术的进步、模组化平台架构的建构以及连接发现与应用的成熟生态系统的发展。近期技术突破凸显了碱基编辑和先导编辑技术的进步，这些技术减少了对双链机制的依赖，从而提高了特异性并拓展了治疗标靶的范围。同时，诸如TALEN、ZFN和Meganucleases技术等传统平台的持续改进，在那些对标靶性和智慧财产权要求极高的领域，依然展现出独特的优势。

对于从事基因编辑研究和生产的组织而言，评估关税政策的变化如何重塑供应链、筹资策略和跨境业务运作至关重要。

贸易和关税体系的政策变化会对研究材料、供应链以及基因编辑创新转化为可操作解决方案的经济效益产生连锁反应。影响试剂、定序耗材、病毒载体组成或专用设备的关税可能成为筹资策略中的摩擦点，迫使各机构重新评估其采购、库存和供应商多元化策略。因此，实验室和製造商可能需要调整供应商合约和物流安排，以确保营运的连续性并维持研究处理能力。

将平台特性、交付方式、应用领域和最终用户需求连结起来的细分市场分析，有助于策略优先排序和产品定位。

细分市场层面的差异对于理解技术能力如何与应用需求和最终用户需求交织至关重要。从平台角度来看，CRISPR、Meganucleases、TALEN 和 ZFN 之间的差异对标靶选择、智慧财产权策略和生产流程具有重要意义。在 CRISPR 内部，碱基编辑、Cas9 和先导编辑等​​子平台各自具有不同的优点和缺点。碱基编辑减少了对双链的依赖，并根据不同的突变情况细分为基于腺嘌呤和基于胞嘧啶的编辑模式。另一方面，先导编辑无需供体模板即可扩展可实现的精确编辑范围。

区域比较趋势凸显了美洲、欧洲、中东和非洲以及亚太地区在转化能力、监管方法和商业机会方面的差异。

区域趋势持续对基因编辑的研究、开发和实用化应用产生重大影响。在美洲，转化研究、创业投资和临床基础设施的优势为加速治疗计画和扩大生产能力创造了有利条件。此外，该地区拥有紧密的合约研究机构和专业服务公司网络，能够支持从药物发现到临床检验的快速迭代。

独特的平台、合作结构和製造能力如何决定整个基因编辑生态系统的竞争优势和伙伴关係策略。

基因编辑领域的竞争格局是由专有平台、合作联盟和垂直整合策略共同塑造的。掌握差异化编辑技术和递送平台的机构通常利用授权协议、共同开发伙伴关係和策略采购来扩大自身影响力，同时保持其核心技术优势。同时，服务供应商和受託研究机构在降低研发过程中的风险方面发挥着至关重要的作用，它们提供临床前试验、载体生产和法规遵从支援方面的专业知识。

领导者可以采取切实可行的策略和营运步骤，以协调平台选择、交付优化、供应链弹性和相关人员协作，从而确保可持续的竞争优势。

领导者应采取务实的投资组合策略，平衡平台开发、应用导向投资和营运韧性。首先，应优先考虑与组织优势相符的技术路线。在机制方面拥有深厚专业知识的组织可以投资改进起始基因和基础基因编辑，而那些拥有成熟病毒载体能力的组织则可以专注于优化伙伴关係和生产效率。同时，应透过有针对性的合作以及在研发规划早期整合转化终点指标，加强交付和安全性评估能力。

采用透明的混合方法研究设计，结合专家访谈、文献整合和情境测试，以检验有关平台、应用程式和营运的推论。

支持这些发现的研究结合了系统性文献综述、专家访谈以及对技术和应用领域进展的结构化分析。关键工作包括与转化科学家、临床开发经理、生产专家和商业负责人进行对话，以收集关于技术限制、监管参与和营运重点的第一手观点。此外，还使用了包括同行评审文章、监管指导文件和技术白皮书在内的二手资讯来评估平台功能和交付方式。

整合各组织必须协调的科学、营运和政策要求，以便将基因编辑的进步转化为治疗、农业和工业的具体成果。

基因编辑正处于一个关键的十字路口，技术进步、递送创新以及不断变化的监管和政策环境在此交汇，既创造了新的机会，也带来了切实的营运挑战。精准编辑化学的进步和多样化的递送方法拓展了基因编辑的应用范围，使其从治疗项目扩展到农业和工业领域。同时，地缘政治因素、供应链脆弱性以及公众对安全性和透明度日益增长的期望，都要求各组织采取综合策略，将卓越的科学技术与前瞻性的营运能力结合。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按技术平台分類的基因编辑技术市场

  • CRISPR
    • 基础编辑
      • 腺嘌呤碱基编辑
      • 胞嘧啶碱基编辑
    • Cas9
    • 主编
  • Meganucleases
  • TALEN
  • ZFN

第九章：基因编辑技术市场：以交付方式划分

  • 非病毒
    • 电穿孔
    • 脂质奈米颗粒
    • 显微注射
  • 病毒性的
    • 腺结合病毒
    • 慢病毒
    • 逆转录病毒

第十章 基因编辑技术市场：依疾病适应症划分

  • 感染疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌
  • 罕见遗传疾病
    • 囊肿纤维化
    • 镰状细胞贫血症

第十一章 基因编辑技术市场：依应用领域划分

  • 农业
    • 农作物
    • 家畜
  • 工业的
    • 生质燃料
    • 生质塑胶
  • 研究工具
    • 侦测
    • 细胞株工程
    • 图书馆筛检
  • 治疗
    • Ex Vivo
      • 免疫疗法
      • 干细胞疗法
    • In vivo
      • 细胞株基因编辑
      • 体细胞基因编辑

第十二章 基因编辑技术市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 基因编辑技术市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 基因编辑技术市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基因编辑技术市场

第十六章：中国基因编辑技术市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • AMS Biotechnology Ltd.
  • Beam Therapeutics Inc.
  • Caribou Biosciences, Inc.
  • Cellectis SA
  • Creative Biogene
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Ltd.
  • Inscripta, Inc.
  • Integrated DNA Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck Group
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Precision BioSciences, Inc.
  • Sangamo Therapeutics, Inc.
  • Synthego Corporation
  • Takara Bio Inc.
  • Tecan Trading AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-2E76C3E47FBE

The Gene Editing Technologies Market was valued at USD 20.59 billion in 2025 and is projected to grow to USD 23.17 billion in 2026, with a CAGR of 14.78%, reaching USD 54.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.59 billion
Estimated Year [2026] USD 23.17 billion
Forecast Year [2032] USD 54.08 billion
CAGR (%) 14.78%

A succinct orientation to contemporary gene editing that outlines technological advances, translational momentum, and strategic considerations for stakeholders across sectors

The past decade has seen gene editing evolve from a promising laboratory technique into a foundational tool reshaping biomedical research, agricultural science, and industrial biotechnology. Advances in nuclease design, delivery systems, and editing precision have enabled researchers to interrogate biological systems with unprecedented resolution, while clinical programs and translational pipelines have moved increasingly from conceptual demonstration toward therapeutic application. As a result, stakeholders across disciplines are recalibrating portfolios, investment priorities, and collaborative models to capture the scientific and commercial potential of these platforms.

This introduction synthesizes the current landscape by focusing on the converging technical advances and ecosystem dynamics that matter to executives and R&D leaders. It highlights the interplay between platform innovation and downstream application, the growing importance of delivery and safety considerations, and the shifting expectations around regulatory dialogues and public acceptance. By foregrounding these themes, the narrative sets a pragmatic foundation for subsequent sections that address structural shifts, policy impacts, segmentation intelligence, regional patterns, and actionable recommendations for organizations seeking to navigate the gene editing frontier.

How recent technical breakthroughs in editing chemistry, delivery modalities, and regulatory engagement are recalibrating innovation pathways and commercial collaborations

Gene editing is undergoing transformative shifts driven by refinements in precision chemistry, modular platform architectures, and a maturing ecosystem that links discovery to application. Recent technical milestones have emphasized base editing and prime editing modalities that reduce reliance on double-strand break mechanisms, thereby improving specificity and broadening the set of treatable targets. At the same time, incremental improvements in traditional platforms such as TALEN, ZFN, and meganuclease technologies continue to offer niche advantages where bespoke targeting or intellectual property considerations prevail.

Concurrently, the landscape is changing as delivery innovations-ranging from lipid nanoparticle formulations to viral vector engineering-reshape how therapies reach target tissues and how agricultural or industrial edits are deployed. This nexus of platform sophistication and delivery robustness is catalyzing new partnerships between biotechnology developers, contract research providers, and advanced manufacturing specialists. Moreover, ethical and regulatory discourse has intensified, prompting more proactive engagement between developers and regulators to define acceptable risk thresholds and clinical endpoints. Together, these shifts are creating an environment where iterative technical improvement and pragmatic governance combine to accelerate translational pathways and broaden the practical reach of gene editing applications.

Assessing how evolving tariff policies reshape supply chains, procurement strategies, and cross-border operational choices for entities engaged in gene editing research and production

Policy changes in trade and tariff regimes can have cascading effects on research inputs, supply chains, and the economics of translating gene editing innovations into deployable solutions. Tariffs that affect reagents, sequencing consumables, viral vector components, or specialized equipment create friction points in procurement strategies, forcing organizations to reassess sourcing, inventory, and vendor diversification. In turn, laboratories and manufacturers may alter supplier contracts and logistics arrangements to preserve continuity of operations and maintain research throughput.

Beyond procurement, tariffs can influence strategic decisions such as location of preclinical manufacturing, choices about in-house versus outsourced capabilities, and the structuring of cross-border collaborations. Academic centers, contract research organizations, and biopharmaceutical developers may respond by consolidating key operations in tariff-favored jurisdictions or by deepening partnerships with regional suppliers. Importantly, these adjustments often lead to increased emphasis on supply chain visibility and risk management, with teams investing in scenario planning and buffer strategies. In aggregate, tariff dynamics reshape the operational calculus for organizations engaging in gene editing R&D and production, underscoring the need for adaptable sourcing frameworks and proactive commercial planning.

Segment-focused analysis linking platform characteristics, delivery choices, application domains, and end-user needs to inform strategic prioritization and product positioning

Segment-level differentiation is central to understanding where technical capabilities intersect with application demand and end-user needs. On the platform side, distinctions among CRISPR, meganuclease, TALEN, and ZFN are consequential for target selection, intellectual property strategy, and manufacturing workflows. Within CRISPR, sub-platforms such as Base Editing, Cas9, and Prime Editing offer distinct trade-offs: Base Editing reduces double-strand break reliance and is subdivided into Adenine Base Editing and Cytosine Base Editing modalities that address different mutational contexts, while Prime Editing expands the range of precise edits that can be achieved without donor templates.

Application segmentation further clarifies use cases, spanning Agricultural pursuits with crops and livestock applications, Industrial uses focused on biofuels and bioplastics, Research Tools encompassing assays, cell line engineering, and library screening, and Therapeutic development that separates Ex Vivo approaches-such as immunotherapy and stem cell therapy-from In Vivo strategies, which include germline and somatic editing. End users vary accordingly; large and small biopharmaceutical companies, clinical and preclinical contract research organizations, clinics and hospitals within medical centers, and academic research groups and government laboratories each demand different data packages, regulatory support, and commercialization roadmaps. Delivery method choices between Nonviral techniques like electroporation, lipid nanoparticle formulations, and microinjection, and Viral vectors such as adeno-associated virus, lentivirus, and retrovirus, influence development timelines, scalability, and safety profiles. Disease indication prioritization, including infectious diseases, oncology with its hematological and solid tumor subcategories, and rare genetic disorders such as cystic fibrosis and sickle cell disease, shapes clinical endpoints and patient recruitment strategies. Together, these segmentation vectors provide a multidimensional framework for aligning technology selection, development pathways, and commercial tactics with specific organizational goals.

Comparative regional dynamics that highlight differentiated translational capacity, regulatory approaches, and operational opportunities across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to exert a strong influence on the trajectory of gene editing research, development, and deployment. In the Americas, strengths in translational research, venture capital formation, and clinical infrastructure create favorable conditions for accelerating therapeutic programs and scaling manufacturing capabilities. This regional ecosystem also hosts a dense network of contract research providers and specialized service firms that support rapid iteration from discovery to clinical validation.

The Europe, Middle East & Africa region presents a heterogeneous landscape in which robust academic ecosystems and well-developed regulatory frameworks coexist with jurisdictions that are still building advanced manufacturing and clinical trial capacity. Policy variability across countries requires careful navigation, yet the region's emphasis on ethical oversight and patient safety frequently leads to close regulatory engagement and high standards for clinical evidence. In the Asia-Pacific region, expanding biotechnology talent pools, growing manufacturing capacity, and proactive industrial strategies have led to intensified activity across both therapeutic and agricultural applications. Cross-border partnerships, regional supply chains, and investments in next-generation facilities characterize this area, creating options for organizations seeking operational redundancy and cost-effective production. These regional patterns underscore the necessity of tailoring commercialization strategies, regulatory approaches, and partner selection to the specific strengths and constraints of each geography.

How proprietary platforms, alliance structures, and manufacturing capabilities define competitive advantage and partnership strategies across the gene editing ecosystem

Competitive dynamics in the gene editing landscape are shaped by a combination of proprietary platforms, collaborative alliances, and vertical integration strategies. Organizations that control differentiated editing modalities or delivery platforms frequently leverage licensing arrangements, co-development partnerships, and strategic sourcing to extend their reach while retaining core technological advantages. Concurrently, service providers and contract research organizations play a pivotal role in de-risking development pathways by offering specialized capabilities in preclinical testing, vector manufacturing, and regulatory support.

Intellectual property management, manufacturing scale-up, and clinical trial design are recurring battlegrounds where firms seek durable advantages. Companies with integrated manufacturing capabilities can accelerate timelines and exert greater control over quality, whereas those focused on platform refinement may rely on partnerships to commercialize downstream applications. Additionally, cross-sector collaborations that combine academic discovery with commercial development continue to be a fertile source of innovation, particularly when they address translational bottlenecks such as delivery, immunogenicity mitigation, and long-term safety monitoring. For decision-makers, understanding how prospective partners or rivals configure these capabilities is essential when evaluating alliance fit, outsourcing decisions, and in-licensing opportunities.

Practical strategic and operational steps leaders can implement to align platform choices, delivery optimization, supply chain resilience, and stakeholder engagement for durable advantage

Leaders should adopt a pragmatic portfolio approach that balances platform development with application-focused investments and operational resilience. Begin by prioritizing technology routes that align with institutional strengths: organizations with deep mechanistic expertise may invest in prime editing or base editing refinement, while those with established viral vector competencies might focus on optimizing tropism and manufacturing throughput. Simultaneously, strengthen delivery and safety assessment capabilities through targeted partnerships and by integrating translational endpoints early in development planning.

Operationally, diversify supply chains and engage in scenario planning to mitigate tariff-related and geopolitical risks. Contractual arrangements that incorporate dual sourcing, regional manufacturing options, and inventory buffering will reduce exposure to procurement disruptions. On the commercial front, cultivate relationships with clinical networks, payers, and patient advocacy groups to ensure that development programs reflect realistic clinical pathways and adoption considerations. Finally, invest in regulatory engagement and ethical communications to build trust with stakeholders and streamline approvals. By executing on these interconnected actions, institutions can better position themselves to translate technical advances into durable clinical, agricultural, or industrial outcomes.

A transparent mixed-method research design that integrates expert interviews, literature synthesis, and scenario testing to validate platform, application, and operational inferences

The research underpinning these insights combined systematic literature review, expert interviews, and structured analysis of technology and application trajectories. Primary engagements included conversations with translational scientists, clinical development leads, manufacturing experts, and commercial strategists to capture first-hand perspectives on technical constraints, regulatory interactions, and operational priorities. Secondary sources consisted of peer-reviewed publications, regulatory guidance documents, and technical white papers that informed assessments of platform capabilities and delivery approaches.

To ensure rigor, the methodology emphasized triangulation across data types and stakeholders, cross-checking claims about platform performance against empirical evidence from preclinical and early clinical studies, and validating operational inferences through practitioner feedback. Scenario analysis was used to explore the implications of policy shifts and supply chain disruptions, while segmentation logic was constructed to reflect the practical decision nodes that organizations face when selecting platforms, applications, delivery methods, and end-user targets. This mixed-method approach produced a structured evidence base that supports actionable recommendations while maintaining transparency about limits and assumptions.

Synthesis of the scientific, operational, and policy imperatives that organizations must reconcile to translate gene editing advances into tangible therapeutic, agricultural, and industrial outcomes

Gene editing stands at a pivotal juncture where technical progress, delivery innovation, and evolving regulatory and policy environments converge to create new opportunities and real operational challenges. Advances in precision editing chemistries and diversified delivery methods have expanded the range of feasible applications from therapeutic programs to agricultural and industrial uses. At the same time, geopolitical factors, supply chain fragility, and heightened expectations for safety and transparency demand that organizations adopt integrated strategies that combine scientific excellence with operational foresight.

Moving forward, sustained progress will require coordinated investment in delivery science, robust engagement with regulatory and ethical stakeholders, and flexible commercial strategies that reflect regional differences and end-user needs. Organizations that successfully navigate this landscape will be those that marry deep technical capabilities with pragmatic supply chain and partnership choices, and who prioritize the translational steps needed to move from laboratory promise to real-world impact. The conclusion underscores the importance of aligning internal capabilities with external realities to realize the full potential of gene editing technologies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Editing Technologies Market, by Technology Platform

  • 8.1. CRISPR
    • 8.1.1. Base Editing
      • 8.1.1.1. Adenine Base Editing
      • 8.1.1.2. Cytosine Base Editing
    • 8.1.2. Cas9
    • 8.1.3. Prime Editing
  • 8.2. Meganuclease
  • 8.3. TALEN
  • 8.4. ZFN

9. Gene Editing Technologies Market, by Delivery Method

  • 9.1. Nonviral
    • 9.1.1. Electroporation
    • 9.1.2. Lipid Nanoparticle
    • 9.1.3. Microinjection
  • 9.2. Viral
    • 9.2.1. Adeno Associated Virus
    • 9.2.2. Lentivirus
    • 9.2.3. Retrovirus

10. Gene Editing Technologies Market, by Disease Indication

  • 10.1. Infectious Diseases
  • 10.2. Oncology
    • 10.2.1. Hematological Malignancies
    • 10.2.2. Solid Tumors
  • 10.3. Rare Genetic Disorders
    • 10.3.1. Cystic Fibrosis
    • 10.3.2. Sickle Cell Disease

11. Gene Editing Technologies Market, by Application

  • 11.1. Agricultural
    • 11.1.1. Crops
    • 11.1.2. Livestock
  • 11.2. Industrial
    • 11.2.1. Biofuels
    • 11.2.2. Bioplastics
  • 11.3. Research Tools
    • 11.3.1. Assays
    • 11.3.2. Cell Line Engineering
    • 11.3.3. Library Screening
  • 11.4. Therapeutic
    • 11.4.1. Ex Vivo
      • 11.4.1.1. Immunotherapy
      • 11.4.1.2. Stem Cell Therapy
    • 11.4.2. In Vivo
      • 11.4.2.1. Germline Gene Editing
      • 11.4.2.2. Somatic Gene Editing

12. Gene Editing Technologies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Editing Technologies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Editing Technologies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Editing Technologies Market

16. China Gene Editing Technologies Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. AMS Biotechnology Ltd.
  • 17.7. Beam Therapeutics Inc.
  • 17.8. Caribou Biosciences, Inc.
  • 17.9. Cellectis SA
  • 17.10. Creative Biogene
  • 17.11. CRISPR Therapeutics AG
  • 17.12. Editas Medicine, Inc.
  • 17.13. GenScript Biotech Corporation
  • 17.14. Horizon Discovery Ltd.
  • 17.15. Inscripta, Inc.
  • 17.16. Integrated DNA Technologies, Inc.
  • 17.17. Intellia Therapeutics, Inc.
  • 17.18. Lonza Group Ltd.
  • 17.19. Mammoth Biosciences, Inc.
  • 17.20. Merck Group
  • 17.21. New England Biolabs, Inc.
  • 17.22. OriGene Technologies, Inc.
  • 17.23. Precision BioSciences, Inc.
  • 17.24. Sangamo Therapeutics, Inc.
  • 17.25. Synthego Corporation
  • 17.26. Takara Bio Inc.
  • 17.27. Tecan Trading AG
  • 17.28. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE EDITING TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE EDITING TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SICKLE CELL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SICKLE CELL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 296. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 298. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 299. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 300. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 301. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 302. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 303. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 304. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY RARE GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 306. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 308. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2032 (USD MILLION)
  • TABLE 309. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2032 (USD MILLION)
  • TABLE 310. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 311. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 312. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)

TABLE 315.